hcyt - HCYT STOCK NEWS

H-CYTE, Inc. (OTCQB: HCYT) announced a letter of intent to acquire SkinDisc, a patent pending tissue regeneration technology, expected to close within 30 days. This acquisition aligns with H-CYTE's vision to build a diverse asset portfolio and transition into a hybrid-biopharmaceutical company. SkinDisc has shown early clinical success, treating 250 patients with healing achieved in 4-9 weeks, significantly faster than traditional methods. H-CYTE plans to submit a De Novo 510(k) request for SkinDisc by mid-2023, addressing a market opportunity worth $2 billion.

H-CYTE, Inc. has completed the acquisition of Jantibody, enhancing its asset portfolio in the medical biosciences sector. This strategic acquisition focuses on treating ovarian cancer and has potential applications for other diseases. H-CYTE plans to submit a Pre-IND for Jantibody in 2022, aiming for Orphan Drug Designation to secure 7 years of market exclusivity. The acquisition is supported by equity proceeds, marking a significant step in H-CYTE's transition to a hybrid-biopharmaceutical company.

H-CYTE, Inc. (OTCQB: HCYT) has announced its acquisition of Jantibody, an immunotherapeutic agent under investigation for treating ovarian cancer, expected to close within 30 days. This milestone is part of H-CYTE's strategy to diversify its asset portfolio. The company plans to submit a Pre-IND submission for Jantibody in the latter half of 2022, aiming for Orphan Drug Designation that grants 7-year market exclusivity. Jantibody has shown strong efficacy in preclinical studies for ovarian cancer and potentially other cancers.

H-CYTE, Inc. announces a 1-for-1,000 reverse stock split effective June 13, 2022, approved by stockholders on March 23, 2022. This decision aims to increase the trading price of its shares to meet NASDAQ uplisting requirements. As a result, the number of shares will decrease from approximately 255 million to about 255 thousand. The reverse split will adjust the number of outstanding shares, options, and warrants accordingly. Issuer Direct will handle the share adjustments for stockholders without requiring action on their part.

H-CYTE, Inc. announced the exercise of 75,257,511 warrants, generating $1,053,605 in capital. This funding will aid the company in transitioning to a hybrid-biopharmaceutical model through strategic acquisitions and bolster general working capital. Additionally, holders of the exercised warrants received inducement warrants with a five-year term at an exercise price of $0.014. CEO Michael Yurkowsky emphasized that this capital injection will facilitate the expansion of new diagnostics, therapeutics, and medical devices, enhancing the company's commitment to treating chronic conditions and orphan diseases.

H-CYTE, Inc. (OTCQB: HCYT) has announced a letter of intent to acquire Catheter Precision, Inc., targeting the cardiac electrophysiology market, a multi-billion dollar sector. Catheter Precision specializes in innovative, FDA-approved devices that enhance treatment for cardiac arrhythmias, featuring a robust business model with high gross margins. The acquisition is anticipated to create significant market opportunities by leveraging existing reimbursement codes. H-CYTE CEO Michael Yurkowsky expressed optimism about the deal, citing Catheter Precision’s advanced technologies and successful leadership.

H-CYTE has appointed Michael Yurkowsky as its new Chief Executive Officer effective immediately. With over 25 years in financial services and a board member since 2019, Yurkowsky aims to enhance shareholder value by reducing cash burn and expanding the product portfolio through an aggressive M&A strategy. He also serves as President and Chairman of Deverra Therapeutics, emphasizing a focus on regenerative medicine and cellular therapeutics to improve chronic health conditions.

H-CYTE, Inc. (OTCQB: HCYT) has rebranded its 'Lung Health Institute' to 'Centers for Respiratory Health' to emphasize its commitment to data-driven, patient-centric care. This strategic move aligns with the company’s innovative PRP-PBMC therapy for chronic lung disorders. CEO Robert Greif highlighted new management and clinical advancements, claiming significant improvements in pulmonary function from real-world studies. A multi-center randomized trial is planned to further evaluate the therapy.

H-CYTE, Inc. (OTCQB: HCYT) announced a successful observational study published in the Journal of Regenerative Medicine & Biology Research, demonstrating significant improvements in lung function and quality of life for COPD patients treated with their PRP-PBMC therapy. Out of 419 participants, 67% showed improved pulmonary function at three months post-treatment, while 83% experienced quality of life enhancements. This study adds to H-CYTE's growing data supporting the efficacy and safety of its regenerative treatments, positioning it as a potential leader in cellular therapeutics.